Ketamine: Not A Simple Treatment, But a Worthy One

Ketamine: Not A Simple Treatment, But a Worthy One

Publication date: May 02, 2021

Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression.

Concepts Keywords
Alabama Psychoactive drugs
Clinic Drugs
Dj Major depressive disorder
Neuropsychopharmacol DF
Psychiatric Nasal administration
Shelton Treatment-resistant depression
Sedatives
Esketamine
Nicotinic antagonists
General anesthetics
NMDA receptor antagonists
Health sciences
Antidepressants

Semantics

Type Source Name
disease MESH major depressive disorder
disease MESH relapse
drug DRUGBANK Esketamine
disease MESH suicidal ideation
drug DRUGBANK Ketamine
disease MESH Depression
disease MESH Suicide
disease MESH mood disorders

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *